Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-2: mevrometostat plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer
CTR20243908Phase 3Active
- Sponsor
- Pfizer
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Mevrometostat + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Started Dec 2024; status: active.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20243908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243908.